plerixafor has been researched along with pemetrexed in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
Hou, S; Kadoch, O; Li, H; Li, J; Li, S; Li, T; Lin, Q; Xie, L; Xu, Z; Yang, YL | 1 |
1 review(s) available for plerixafor and pemetrexed
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for plerixafor and pemetrexed
Article | Year |
---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Experimental study of the inhibition effect of CXCL12/CXCR4 in malignant pleural mesothelioma.
Topics: Animals; Benzylamines; Cell Line, Tumor; Chemokine CXCL12; Cyclams; Female; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds; Luminescent Measurements; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice, Inbred BALB C; Mice, Nude; Pemetrexed; Pleural Neoplasms; Protein Isoforms; Receptors, CXCR4; Signal Transduction | 2019 |